Clinical Trial Detail

NCT ID NCT02784158
Title An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Recruitment No longer available
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Ariad Pharmaceuticals
Indications

non-small cell lung carcinoma

Therapies

Brigatinib

Age Groups: senior adult

Additional content available in CKB BOOST